Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Intra-Cellular Therapies, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 11 months agointracellulartherapies.com
Intra-Cellular Therapies, Inc., a leading biopharmaceutical company based in the United States, focuses on developing innovative treatments for neuropsychiatric diseases. Founded in 2002, the company has made significant strides in the industry, particularly with its flagship product, Caplyta (lumateperone), which has garnered attention for its unique mechanism of action in treating schizophrenia and bipolar depression.
With a strong presence in the US and expanding operations in key global markets, Intra-Cellular Therapies is committed to addressing unmet medical needs through its cutting-edge research and development efforts. The company’s dedication to advancing mental health therapies positions it as a notable player in the biopharmaceutical landscape, with a focus on improving patient outcomes and enhancing quality of life.
72
DitchCarbon score
+30 vs industry average
Intra-Cellular Therapies, Inc.’s score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Intra-Cellular Therapies, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Intra-Cellular Therapies, Inc. yet.
Intra-Cellular Therapies, Inc.'s reported carbon emissions
Intra-Cellular Therapies, Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Johnson & Johnson, and any climate commitments or emissions data may be inherited from this parent organisation.
In terms of climate initiatives, Intra-Cellular Therapies, Inc. aligns with several sustainability efforts cascaded from Johnson & Johnson, including participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These initiatives reflect a commitment to reducing greenhouse gas emissions and transitioning to renewable energy sources, although specific reduction targets for Intra-Cellular Therapies, Inc. have not been disclosed.
As a subsidiary, the company's climate strategies and performance are influenced by Johnson & Johnson's broader sustainability goals, which aim to address climate change and promote environmental stewardship. However, without specific emissions data or reduction targets, it is challenging to assess the company's individual impact on carbon emissions at this time.
Assessing Intra-Cellular Therapies, Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Intra-Cellular Therapies, Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Intra-Cellular Therapies, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Intra-Cellular Therapies, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Johnson & Johnson2030 targetSee details
Active
Carbon Disclosure Project
Inherited from Johnson & JohnsonSign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
Inherited from Johnson & JohnsonSee details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Intra-Cellular Therapies, Inc. yet.
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more